In my clinic, the American disease of the prostate, such as in clinics that see a large number of patients with prostate cancer, prostate cancer, I met that deviate from the established behavior of common adenocarcinomas. One of the forms of the unusual from prostate cancer is a neuroendocrine carcinoma.
neuroendocrine cells found in normal prostate gland, where they have been shown to produce various hormones including serotonin, bombesin, and calcitonin. However, we do not know the role of neuroendocrine cells play in normal prostate biology. In standard adenocarcinoma of the prostate gland, is almost always found in neuroendocrine cells scattered throughout the mass of cancer. In this setting, neuroendocrine cells do not make PSA, did not grow up and have no androgen receptor. In a test tube, although neuroendocrine cells do not grow, a hormone produced by these cells could encourage the growth of adenocarcinoma cells. One report claims that in prostate cancer specimens obtained at surgery, prostate cancer cells near the neuroendocrine cells grow faster than those distant from these cells. This shows that fuel cells may neuroendocrine prostate cancer development. In fact, the greater proportion of the mass consisting of neuroendocrine cancer cells in the diagnosis, the more likely the patient will do poorly from time to time.
While chromogranin A serum marker generally has found the best to detect the development of prostate cancer cells in the neuroendocrine, there is some evidence that more than just a marker. For example, if you add a chromogranin A in prostate cancer cell cultures, triggering the formation of proteins that increase the resistance of cancer cells to treatment.
In prostate cancer research, there are certain classic studies that clearly define the major issues. In 1991, Kadmon, et al. show that high levels of chromogranin hormone resistance evolution made more likely. Moreover, once begin hormonal therapy, chromogranin A levels are elevated in many patients initially, but then will drop back to normal. When staying chromogranin A levels began to rise as high or when the end of hormonal therapy, hormone resistance is likely to follow. This observation has been repeatedly confirmed.
Until now, we have discussed the impact of neuroendocrine cells that can not afford their own growth and where the impact seems to be an effect on prostate adenocarcinoma cells. In small cell carcinoma of the prostate gland we have neuroendocrine cells capable of growing rapidly and spread. Once again, these cells make very little or no androgen receptor PSA and make little or none. While they can make a chromogranin A and other neuroendocrine markers, in many cases they do not make a detectable marker.
neuroendocrine cells found in normal prostate gland, where they have been shown to produce various hormones including serotonin, bombesin, and calcitonin. However, we do not know the role of neuroendocrine cells play in normal prostate biology. In standard adenocarcinoma of the prostate gland, is almost always found in neuroendocrine cells scattered throughout the mass of cancer. In this setting, neuroendocrine cells do not make PSA, did not grow up and have no androgen receptor. In a test tube, although neuroendocrine cells do not grow, a hormone produced by these cells could encourage the growth of adenocarcinoma cells. One report claims that in prostate cancer specimens obtained at surgery, prostate cancer cells near the neuroendocrine cells grow faster than those distant from these cells. This shows that fuel cells may neuroendocrine prostate cancer development. In fact, the greater proportion of the mass consisting of neuroendocrine cancer cells in the diagnosis, the more likely the patient will do poorly from time to time.
While chromogranin A serum marker generally has found the best to detect the development of prostate cancer cells in the neuroendocrine, there is some evidence that more than just a marker. For example, if you add a chromogranin A in prostate cancer cell cultures, triggering the formation of proteins that increase the resistance of cancer cells to treatment.
In prostate cancer research, there are certain classic studies that clearly define the major issues. In 1991, Kadmon, et al. show that high levels of chromogranin hormone resistance evolution made more likely. Moreover, once begin hormonal therapy, chromogranin A levels are elevated in many patients initially, but then will drop back to normal. When staying chromogranin A levels began to rise as high or when the end of hormonal therapy, hormone resistance is likely to follow. This observation has been repeatedly confirmed.
Until now, we have discussed the impact of neuroendocrine cells that can not afford their own growth and where the impact seems to be an effect on prostate adenocarcinoma cells. In small cell carcinoma of the prostate gland we have neuroendocrine cells capable of growing rapidly and spread. Once again, these cells make very little or no androgen receptor PSA and make little or none. While they can make a chromogranin A and other neuroendocrine markers, in many cases they do not make a detectable marker.
0 comments:
Post a Comment